FDA Reverses Huntington’s Gene Therapy Rejection After Leadership Shift

The Food and Drug Administration has reinstated a promising gene therapy for Huntington’s disease after leadership changes at the agency, ending a contentious review process that former officials described as unprecedented. The decision follows the removal of several Trump appointees, including Vinay Prasad, whose rejection of the treatment drew sharp criticism from patient advocates and medical professionals alike.

Huntington’s disease remains one of medicine’s most devastating diagnoses, typically striking in midlife with relentless neurodegeneration that leaves patients with severe motor, cognitive, and psychiatric impairments. With no existing treatments to halt or reverse its progression, the neurodegenerative condition shortens lifespans by an average of 15 to 20 years. The absence of therapeutic options has made the development of UniQure’s experimental drug, AMT-130, a beacon of hope for families grappling with the genetic disorder.

AMT-130 represents a potential breakthrough in precision medicine, delivering a single-dose gene therapy designed to reduce levels of the mutant huntingtin protein—a key driver of the disease. Early clinical trial data has shown remarkable promise, with results indicating a 75% slowdown in disease progression among treated patients. The findings have galvanized the Huntington’s community, where patients and caregivers have rallied for years to advance research and secure regulatory approval for life-changing therapies.

The FDA’s initial rejection of AMT-130 was met with widespread dismay, particularly from ethicists and clinicians who questioned the scientific rigor of the decision. Critics argued that the move disregarded compelling evidence and prioritized policy over patient welfare. Vinay Prasad, a vocal FDA official during the Trump administration, faced backlash for his role in blocking the therapy, with one former regulator calling the rejection "truly evil"—a phrase that underscored the gravity of the decision’s impact on vulnerable patients.

Now, with leadership changes at the agency, the path to approval appears to be reopening. Regulatory experts suggest that the reversal reflects a return to evidence-based decision-making, though the process remains under scrutiny. UniQure has emphasized its commitment to transparency, reaffirming its intent to collaborate closely with the FDA to address any remaining concerns.

As the gene therapy landscape evolves, AMT-130 could set a precedent for treating other neurodegenerative disorders. The outcome of this case may influence future regulatory approaches, particularly for rare diseases where patient advocacy plays a pivotal role. For now, the Huntington’s community holds its breath, hopeful that science will finally offer a reprieve from a condition long considered untreatable.